COLORADO SPRINGS, Colo.,
Oct. 23, 2013 /PRNewswire/ -- Endocan
Corporation (NASDAQ OTC: XCHC) a U.S. Company specializing in
cannabis and cannabinoid formulation-based health and wellness
solutions, issues guidance with regard to the next phase of its new
product releases and international branding campaign through the
Company's marketing launch in the United
States, Canada, and
Europe.
Following the corporate name change to Endocan Corporation and
successful launch of the www.endocan.com website, the Company
enters the final stages of its new product releases through
targeted marketing via licensing arrangements with State approved
dispensaries, and social media outlets. The ultimate goal is
to position Endocan branded products with useful education and
support for those with critical ailments.
In this effort, Endocan has launched a social media campaign
using FaceBook, Twitter, Google+, You Tube, and LinkedIn. The
Endocan social media sites can be found on the home page or
here:
https://www.facebook.com/endocancorp
https://twitter.com/EndocanCorp
https://plus.google.com/u/0/103344439990585364035/posts
http://www.youtube.com/channel/UC7vNLaZBzmCJJF-wNGJkMHQ/vide
http://www.linkedin.com/pub/endocan-corporation/81/a2a/86a
In addition, the Company plans to make available to media
outlets key members of the Company's management for interviews and
to initiate brand building through speaking engagements, public
conference calls, and a road show in early 2014. The airing
of Endocan commercials in top national markets will also be used to
build on brand visibility. Commercial treatments for various
advertisements were prepared earlier this year, and production has
been awaiting the release of the Endocan name and branding.
Endocan's management team has a high degree of media
savvy. Among other individual achievements, management
was involved with the critically acclaimed documentary, American
Drug War 2, a Sacred Cow production, directed by Kevin Booth. The film can be seen at
www.AmericanDrugWar2.com. More national and
international documentary and educational releases are expected in
the near future to help get the word out across the nation.
"We are very impressed with the marketing platforms modeled by
the Endocan team. The Company intends to use all available
media resources to share the progress of the Company and the
stories of cannabis patients. Similar efforts have
supported and matured many early stage companies, such as ours,
into global, socially aware businesses, and we are very excited to
have started that journey," stated Robert
Kane, CFO & Sr VP of Business Development, Endocan
Corporation.
About Endocan Corporation
The brand name Endocan™ was chosen by the Board as a direct
reference to the endocannabinoid system of the human body. The
endocannabinoid system is a group of neuromodulatory compounds and
their receptors that are involved in a variety of fundamental
physiological processes including pain-sensation, immune function,
stress, sleep, mood, appetite, and memory. Cannabinoids from
plants, including those found in the Cannabis genus, as well as
those autonomously produced within living biological systems, work
together in the operation of the endocannabinoid system. The
modulation of this system is the basis for cannabinoid-based
medical treatments to assist patients to improve their health and
well-being.
Endocan Corporation, (FKA The X-Change Corporation) is currently
developing new natural cannabinoid containing products based on
innovative formulations to utilize the unique and potent benefits
of the cannabis and hemp plants. Medicinal properties of cannabis,
and hemp have been known and applied for thousands of years. With
the aid of scientific research, Endocan Corporation is translating
such knowledge into development of effective cannabinoid
formulation-based health and wellness solutions as well as
cosmeceutical, nutraceutical, and food brands throughout the world.
The Company's health and wellness, nutritional, and cosmetics lines
will address personal needs and will evolve with the introduction
of new formulations and products, advancing the Company within the
expanding multibillion-dollar global market.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
words such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events, or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. The Company does not undertake any duty nor does it intend
to update the results of these forward-looking statements.
Endocan Corporation
President
Dr. Dorothy Bray
info@endocan.com
www.endocan.com
+1.866.326.5595
Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
robert.kane@endocan.com
+1.561.420.4824
SOURCE Endocan Corporation